The suscebility of hipertensive patients to contract COVID-19 and develop a serious form of disease
DOI:
https://doi.org/10.33448/rsd-v13i3.45413Keywords:
COVID-19; Hypertension; Renin-Angiotensin System.Abstract
Objective: Establish the relationship between hypertensive patients who contracted COVID-19 and developed severe forms. Methodology: This is an integrative review of the literature carried out in the months of February and March 2024, in the Scielo, Lilacs, MedLine and PubMed databases, using the following descriptors in health sciences: “COVID-19”, “Hypertension” and “Renin-Angiotensin System”, by the Boolean operator AND. In total, 537 studies were found, after the inclusion criteria (articles published between 2019 and 2024, in Portuguese and English) and complete reading, 16 studies were selected to prepare the review. Results: COVID-19 infection causes endothelial dysfunction, exacerbating a pro-inflammatory state. All inflammation causes an increase in renin in the patient's body, accentuating the RAS. Consequently, patients with SAH have a higher concentration of (ACE-II) in the lung epithelia, the SARS-CoV-2 receptor enzyme. Furthermore, the virus inactivates enzymes that are important for reducing the patient's blood pressure. By decreasing ACE II we have an increase in (ACE-I) and this is related to lung injuries and degradation of bradykinin, an important vasodilator and bronchodilator hormone. It is clear that the development of the severe form of the disease in hypertensive patients occurs due to the inflammatory state of the disease, which is exacerbated, such as the imbalance of the RAS due to organ damage. Conclusion: Therefore, any patient with pro-inflammatory conditions tends to have a more severe condition from COVID-19. Concomitantly with hypertension, an increase in ACE-I causes vasoconstriction and bronchoconstriction and a decrease in ACE-II, deregulating other factors that favor thrombogenic events.
References
Angeli, F., Zappa, M., & Verdecchia, P. (2024). Global burden of new-onset hypertension associated with severe acute respiratory syndrome coronavirus 2 infection. European journal of internal medicine, 119, 31–33. https://doi.org/10.1016/j.ejim.2023.10.016
Baral, R., White, M., & Vassiliou, V. S. (2020). Effect of Renin-Angiotensin-Aldosterone System Inhibitors in Patients with COVID-19: a Systematic Review and Meta-analysis of 28,872 Patients. Current atherosclerosis reports, 22(10), 61. https://doi.org/10.1007/s11883-020-00880-6
Bielecka, E., Sielatycki, P., Pietraszko, P., Zapora-Kurel, A., & Zbroch, E. (2024). Elevated Arterial Blood Pressure as a Delayed Complication Following COVID-19-A Narrative Review. International journal of molecular sciences, 25(3), 1837. https://doi.org/10.3390/ijms25031837
Chen, H., Peng, J., Wang, T., Wen, J., Chen, S., Huang, Y., & Zhang, Y. (2023). Counter-regulatory renin-angiotensin system in hypertension: Review and update in the era of COVID-19 pandemic. Biochemical pharmacology, 208, 115370. https://doi.org/10.1016/j.bcp.2022.115370
Devaux, C. A., & Camoin-Jau, L. (2022). An update on angiotensin-converting enzyme 2 structure/functions, polymorphism, and duplicitous nature in the pathophysiology of coronavirus disease 2019: Implications for vascular and coagulation disease associated with severe acute respiratory syndrome coronavirus infection. Frontiers in microbiology, 13, 1042200. https://doi.org/10.3389/fmicb.2022.1042200
Dutsch, A., & Schunkert, H. (2023). RAAS inhibition and beyond-cardiovascular medications in patients at risk of or affected by COVID-19. RAAS-Hemmung und darüber hinaus – Herz-Kreislauf-Medikation bei Patienten mit einem Risiko für oder Erkrankung durch COVID-19. Herz, 48(3), 206–211. https://doi.org/10.1007/s00059-023-05168-4
Elbasan, O., Bayram, F., Yazan, C. D., Apaydın, T., Dashdamirova, S., Polat, H., Arslan, E., Yılmaz, İ., Karimi, N., Şengel, B. E., Yılmaz, S. S., Çelik, Ö. F., Ata, P., Haklar, G., & Gözü, H. (2023). Angiotensin-Converting Enzyme (ACE) level, but not ACE gene polymorphism, is associated with prognosis of COVID-19 infection: Implications for diabetes and hypertension. PloS one, 18(7), e0288338. https://doi.org/10.1371/journal.pone.0288338
Jamil, G., Ataee, M., Esmaeili, V., Chamani, S., Rezaei, A., & Naghizadeh, A. (2023). Characterization of the angiotensin-converting enzyme 2 (ACE2), the main receptor for the SARS-CoV-2 virus. American journal of clinical and experimental immunology, 12(3), 24–44.
Kartchner, D., McCoy, K., Dubey, J., Zhang, D., Zheng, K., Umrani, R., Kim, J. J., & Mitchell, C. S. (2023). Literature-Based Discovery to Elucidate the Biological Links between Resistant Hypertension and COVID-19. Biology, 12(9), 1269. https://doi.org/10.3390/biology12091269
Kounis, N. G., Gogos, C., de Gregorio, C., Hung, M. Y., Kounis, S. N., Tsounis, E. P., Assimakopoulos, S. F., Pourmasumi, S., Mplani, V., Servos, G., Dousdampanis, P., Plotas, P., Michalaki, M. A., Tsigkas, G., Grammatikopoulos, G., Velissaris, D., & Koniar, I. (2024). "When," "Where," and "How" of SARS-CoV-2 Infection Affects the Human Cardiovascular System: A Narrative Review. Balkan medical journal, 41(1), 7–22. https://doi.org/10.4274/balkanmedj.galenos.2023.2023-10-25
Kurdi, A., Mueller, T., & Weir, N. (2023). An umbrella review and meta-analysis of renin-angiotensin system drugs use and COVID-19 outcomes. European journal of clinical investigation, 53(2), e13888. https://doi.org/10.1111/eci.13888
Lima, F. B., Muniz, F. W. M. G., Meneses, G. C., Bezerra, K. C., Moreira, C. N., Aguiar, A. P., Nascimento, J. C. R., Veras de S Freitas, T., de Bruin, P. F. C., Pereira, E. D. B., Daher, E. F., & Oriá, R. B. (2024). Influence of angiotensin receptor and converting enzyme blockers therapy in the respiratory outcome of COVID-19 hospitalized patients. Medicina clinica, 162(4), 163–169. https://doi.org/10.1016/j.medcli.2023.10.004
Liu, Q., Fu, W., Zhu, C. J., Ding, Z. H., Dong, B. B., Sun, B. Q., & Chen, R. C. (2023). Effect of continuing the use of renin-angiotensin system inhibitors on mortality in patients hospitalized for coronavirus disease 2019: a systematic review, meta-analysis, and meta-regression analysis. BMC infectious diseases, 23(1), 53. https://doi.org/10.1186/s12879-023-07994-7
Martínez-Del Río, J., Piqueras-Flores, J., Nieto-Sandoval Martín de la Sierra, P., Negreira-Caamaño, M., Águila-Gordo, D., Mateo-Gómez, C., Salas-Bravo, D., & Rodríguez-Martínez, M. (2020). Comparative analysis between the use of renin-angiotensin system antagonists and clinical outcomes of hospitalized patients with COVID-19 respiratory infection. Medicina clinica (English ed.), 155(11), 473–481. https://doi.org/10.1016/j.medcle.2020.07.013
Muntner, P., Foti, K., Wang, Z., Alanaeme, C. J., Choi, E., Bress, A. P., Shimbo, D., & Kronish, I. (2023). Discontinuation of Renin-Angiotensin System Inhibitors During the Early Stage of the COVID-19 Pandemic. American journal of hypertension, 36(7), 404–410. https://doi.org/10.1093/ajh/hpad027
Oliveira, K. B., de Melo, I. S., da Silva, B. R. M., Oliveira, K. L. D. S., Sabino-Silva, R., Anhezini, L., Katayama, P. L., Santos, V. R., Shetty, A. K., & de Castro, O. W. (2023). SARS-CoV-2 and Hypertension: Evidence Supporting Invasion into the Brain Via Baroreflex Circuitry and the Role of Imbalanced Renin-Angiotensin-Aldosterone-System. Neuroscience insights, 18, 26331055231151926. https://doi.org/10.1177/26331055231151926
Shams, E., Kamalumpundi, V., Cheng, L., Taiwo, A., Shibli-Rahhal, A., Dokun, A. O., & Correia, M. L. G. (2023). Association between RAAS Antagonism and COVID-19-related Mortality in Patients with Overweight/Obesity-related Hypertension: A Retrospective Cohort Study. Associação entre o Antagonismo do Sistema Renina-Angiotensina-Aldosterona e a Mortalidade Relacionada à COVID-19 em Pacientes com Hipertensão Relacionada ao Sobrepeso/Obesidade: um Estudo Retrospectivo de Coorte. Arquivos brasileiros de cardiologia, 120(4), e20220277. https://doi.org/10.36660/abc.20220277
Tanzadehpanah, H., Lotfian, E., Avan, A., Saki, S., Nobari, S., Mahmoodian, R., Sheykhhasan, M., Froutagh, M. H. S., Ghotbani, F., Jamshidi, R., & Mahaki, H. (2023). Role of SARS-COV-2 and ACE2 in the pathophysiology of peripheral vascular diseases. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 166, 115321. https://doi.org/10.1016/j.biopha.2023.115321
Teng, S., & Tang, Q. (2020). ACE2 enhance viral infection or viral infection aggravate the underlying diseases. Computational and structural biotechnology journal, 18, 2100–2106. https://doi.org/10.1016/j.csbj.2020.08.002
Vallejo Ardila, D. L., Tamayo Cáceres, Y. R., & Munive, A. A. (2020). Uso terapéutico de los inhibidores de la enzima convertidora de angiotensina en pacientes con COVID-19: las «dos caras de la moneda» [Therapeutic use of angiotensin converting enzyme inhibitors in patients with COVID-19: the “two sides of the coin”]. Revista Colombiana De Cardiologi´a, 27(4), 212–222. https://doi.org/10.1016/j.rccar.2020.07.001
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Carlos Kaylan Souza Batista; João Marcelo Inácio Gomes; Alcides Leite de Amorim Júnior; Rebeca Targino Falcão Farias; Caio Hamad Pereira Gomes; João Saraiva Lins Neto; Luiz Nicolas Soares Ribeiro de Andrade; Thainara Félix Diniz Araújo; Ana Caroline Paraguay Martins; Victor de Medeiros Cabral; Emanuel Caetano Saraiva Cavalcanti; João Vitor Amorim Pereira
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:
1) Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
2) Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
3) Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.
